Targeted-therapy and imaging response: A new paradigm for clinical evaluation?

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 259-265

  Milano, Amalia ^a   Perri, Francesco ^b   Ciarmiello, Andrea ^c   Caponigro, Francesco ^b  

^a San Bartolomeo Hospital   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SAndrea Hospital La Spezia   (Italy)

Author keywords

CT; PET; RECIST 1.1 criteria; RECISTcriteria; Solid tumors; Targeted therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; FLUORODEOXYGLUCOSE F 18;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL TUMOR; HUMAN; LIVER CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; RADIOPHARMACEUTICALS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 80051763253     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575540     Document Type: Article

References (79)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-16.
2. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22(22): 4442-5.
3. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20(22): 4478-84.
4. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-81.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-42.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378-90.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-32.
8. Bogaerts J, Ford R, Sargent D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 2009; 45(2): 248-60.
9. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2010; 20(6): 1456-67.
10. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009; 50 Suppl 1: 21S-30S.
11. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-86.
12. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13 Suppl 2: 4-7.
13. Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 Suppl 2: 8-13.
14. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37(2): 429-42.
15. Watanabe H, Kunitoh H, Yamamoto S, et al. Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. Cancer Sci 2006; 97(3): 214-8.
16. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18FFDG PET in colorectal cancer: a systematic review. J Nucl Med 2009; 50 Suppl 1: 43S-54S.
17. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 Suppl 1: 122S-50S.
18. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985; 144(2): 261-5.
19. Matsuoka H, Masaki T, Sugiyama M, Atomi Y, Ohkura Y, Sakamoto A. Morphological characteristics of lateral pelvic lymph nodes in rectal carcinoma. Langenbecks Arch Surg 2007; 392(5): 543-7.
20. Schwartz LH, Colville JA, Ginsberg MS, et al. Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Ann Oncol 2006; 17(6): 1018-23.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-47.
22. Moskowitz CS, Jia X, Schwartz LH, Gonen M. A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 2009; 45(2): 300-10.
23. Verweij J, Therasse P, Eisenhauer E. Cancer clinical trial outcomes: any progress in tumor-size assessment? Eur J Cancer 2009; 45(2): 225-7.
24. Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009; 45(2): 261-7.
25. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26(4): 620-5.
26. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26(4): 626-32.
27. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25(9): 1107-13.
28. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25(13): 1760-4.
29. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25(13): 1753-9.
30. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35(13): 1773-82.
31. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344(14): 1052-6.
32. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183(6): 1619-28.
33. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45(3): 357-65.
34. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidencebased management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23(11): 1535-47.
35. Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 2006; 9(3): 125-32.
36. Llovet J.M, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100(10): 698-711.
37. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099-109.
38. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59(5): 561-74.
39. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998; 27(4): 951-8.
40. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41(5): 864-80.
41. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27(1): 55-76.
42. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24(26): 4293-300.
43. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35(3): 421-30.
44. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319): 1734-9.
45. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40(6): 1352-60.
46. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29(4): 522-9.
47. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46(3): 474-81.
48. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115(3): 616-23.
49. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: RECISTing a step backwards. Clin Cancer Res 2005; 11(14): 5223-32.
50. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15(2): 257-60.
51. Nowak AK. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 2005; 49 Suppl 1: S37-40.
52. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004; 43(1): 63-9.
53. Watanabe H, Yamamoto S, Kunitoh H, et al. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci 2003; 94(11): 1015-20.
54. Gietema HA, Schaefer-Prokop CM, Mali WP, Groenewegen G, Prokop M. Pulmonary nodules: Interscan variability of semiautomated volume measurements with multisection CT-- influence of inspiration level, nodule size, and segmentation performance. Radiology 2007; 245(3): 888-94.
55. Sumikawa H, Johkoh T, Nagareda T, et al. Pulmonary adenocarcinomas with ground-glass attenuation on thin-section CT: quantification by three-dimensional image analyzing method. Eur J Radiol 2008; 65(1): 104-11.
56. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11(5): 873-8.
57. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18(19): 3390-9.
58. Weiss GB, Bunce H, Hokanson JA. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. Control Clin Trials 1983; 4(1): 43-52.
59. Birchard KR, Hoang JK, Herndon JE, Patz EF. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009; 115(3): 581-6.
60. Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 2003; 16(11): 1102-8.
61. Lara PN, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008; 26(3): 463-7.
62. Junker K Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 2001; 120(5): 1584-91.
63. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM. Tumor regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997; 123(9): 469-77.
64. Hicks RJ. Role of 18F-FDG PET in assessment of response in nonsmall cell lung cancer. J Nucl Med 2009; 50 Suppl 1: 31S-42S.
65. Vansteenkiste J, Dooms C. Positron emission tomography in nonsmall cell lung cancer. Curr Opin Oncol 2007; 19(2): 78-83.
66. Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54(4): 1024-35.
67. Eschmann SM., Friedel G, Paulsen F, et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2007; 55(2): 165-71.
68. Eschmann SM, Friedel G, Paulsen F, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007; 34(4): 463-71.
69. Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schafers HJ. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004; 128(6): 892-9.
70. Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004; 60(2): 412-8.
71. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348(25): 2500-7.
72. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21(7): 1285-92.
73. Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005; 49(1): 95-108.
74. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343(4): 254-61.
75. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21(14): 2651-7.
76. Yamamoto Y, Nishiyama Y, Monden T, et al. Correlation of FDGPET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006; 33(2): 140-7.
77. Kong FM, Frey KA, Quint LE, et al. A pilot study of[18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non smallcell lung cancer. J Clin Oncol 2007; 25(21): 3116-23.
78. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med 2009; 50 Suppl 1: 55S-63S.
79. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005; 46(7): 1144-50.